CFRX

ContraFect Corporation (CFRX) | Rumor.io

ContraFect

CFRX

Attention (50-day avg)0%

Attention rank (50-day avg)—

Bullish sentiment (50-day avg)—

Price to earnings ratio0

Market capitalization0

Earnings per share0

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)0

Social

What share of all stock conversation is about CFRX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Nov 9

ContraFect Corporation (CFRX) is being delisted from the NASDAQ on November 9 due to failure to meet the minimum stockholder equity requirement of $2.5m.
The company's stock price is currently at $0.23, up 2.84% on the day.
CFRX is trading on the OTC Pink market after being delisted from the NASDAQ.

Generated by AI

Sentiment

Of the messages about CFRX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	94.74% +11.15
Bearish	—	—	—	5.26% -11.15

Bullish· Jun 9

$CFRX is expected to break through $2.05 and potentially reach $2.40.
$CFRX is one of the top two plays with 100% potential, according to a market analyst.
$CFRX has shown strong positive movement, increasing by 4.4% and is considered a solid trade.

Bearish· Apr 17

ContraFect Corporation's ($CFRX) float is only 500K, making it vulnerable to short selling.
The stock's 52-week high of $363.30 is a significant target for sellers, indicating a substantial drop from current levels.
$CFRX's recent price action, including a 20.59% drop in 15 minutes, suggests a strong downward trend that may continue.

Generated by AI

Topics

Of the messages about CFRX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	0%	0%
Announcements	—	—	0%	79.49%
Controversies	—	—	0%	0%
Earnings	—	—	0%	0%
Macro	—	—	0%	0%
Technical Analysis	—	—	100%	20.51%

Announcements· Oct 16

ContraFect Corporation's ($CFRX) CF-370 has received FDA clearance to proceed with a Phase 1 clinical study for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia.
The FDA has completed a safety review of the IND application for CF-370, allowing the company to move forward with the clinical study.
ContraFect Corporation's stock ($CFRX) has risen significantly following the announcement, with a gain of over 29% in a single day.

Technical Analysis· Jun 9

The technical analysis suggests that $CFRX has a strong potential to break through $2.05 and reach $2.40.
The 15-minute and 30-minute charts show a channel down pattern and bearish chart, with key support levels at $1.75 and $1.65, and key resistance level at $2.00.
The price action has been holding within a tight range, with a potential monster spot at $2.13, which could lead to a break and a move to new highs.

Generated by AI

Community

Of the messages about CFRX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	0%	55.28%
Newcomers	—	—	100%	44.72%

Regulars· Oct 16

ContraFect Corporation has announced FDA clearance of the CF-370 IND application, allowing the company to proceed with a Phase 1 clinical study.
The company's stock price is up 34% pre-market and currently trading at $0.77.
The FDA clearance may signal a significant step forward for ContraFect's development pipeline, potentially leading to a payday for investors.

Newcomers· Oct 16

The newcomer is focusing on ContraFect Corporation's ($CFRX) resistance levels at 1.10, 1.18, 1.23, and 1.30, indicating a potential small price push.
The newcomer is interested in ContraFect Corporation ($CFRX) as a stock to watch, possibly due to its recent price movement and potential for further growth.
The newcomer is considering ContraFect Corporation ($CFRX) as a short squeeze/Low float runner play, potentially due to its low float and high short interest, making it a speculative investment opportunity.

Generated by AI

Also Discussed

Investors talking about CFRX also mention

#	Name	Attention
1	SCYNEXIS, Inc. Common StockSCYX	0%-0.02
2	BLCM - Bellicum Pharmaceuticals, Inc.	——
3	PBLA - Panbela Therapeutics, Inc.	——
4	Wisa Technologies Inc.WISA	0%new
5	AMAM - Ambrx Biopharma Inc.	——
6	Mobiquity Technologies Inc.MOBQ	0%new
7	Ocean Biomedical Inc.OCEA	0%0
8	Quhuo LimitedQH	0%0
9	FRTX - Fresh Tracks Therapeutics, Inc.	——
10	RVLP - RVL Pharmaceuticals plc	——

ContraFect Corporation

Location

Social

What share of all stock conversation is about CFRX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Nov 9

ContraFect Corporation (CFRX) is being delisted from the NASDAQ on November 9 due to failure to meet the minimum stockholder equity requirement of $2.5m.
The company's stock price is currently at $0.23, up 2.84% on the day.
CFRX is trading on the OTC Pink market after being delisted from the NASDAQ.

Generated by AI

Sentiment

Of the messages about CFRX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	94.74% +11.15
Bearish	—	—	—	5.26% -11.15

Bullish· Jun 9

$CFRX is expected to break through $2.05 and potentially reach $2.40.
$CFRX is one of the top two plays with 100% potential, according to a market analyst.
$CFRX has shown strong positive movement, increasing by 4.4% and is considered a solid trade.

Bearish· Apr 17

ContraFect Corporation's ($CFRX) float is only 500K, making it vulnerable to short selling.
The stock's 52-week high of $363.30 is a significant target for sellers, indicating a substantial drop from current levels.
$CFRX's recent price action, including a 20.59% drop in 15 minutes, suggests a strong downward trend that may continue.

Generated by AI

Topics

Of the messages about CFRX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	0%	0%
Announcements	—	—	0%	79.49%
Controversies	—	—	0%	0%
Earnings	—	—	0%	0%
Macro	—	—	0%	0%
Technical Analysis	—	—	100%	20.51%

Announcements· Oct 16

ContraFect Corporation's ($CFRX) CF-370 has received FDA clearance to proceed with a Phase 1 clinical study for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia.
The FDA has completed a safety review of the IND application for CF-370, allowing the company to move forward with the clinical study.
ContraFect Corporation's stock ($CFRX) has risen significantly following the announcement, with a gain of over 29% in a single day.

Technical Analysis· Jun 9

The technical analysis suggests that $CFRX has a strong potential to break through $2.05 and reach $2.40.
The 15-minute and 30-minute charts show a channel down pattern and bearish chart, with key support levels at $1.75 and $1.65, and key resistance level at $2.00.
The price action has been holding within a tight range, with a potential monster spot at $2.13, which could lead to a break and a move to new highs.

Generated by AI

Community

Of the messages about CFRX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	0%	55.28%
Newcomers	—	—	100%	44.72%

Regulars· Oct 16

ContraFect Corporation has announced FDA clearance of the CF-370 IND application, allowing the company to proceed with a Phase 1 clinical study.
The company's stock price is up 34% pre-market and currently trading at $0.77.
The FDA clearance may signal a significant step forward for ContraFect's development pipeline, potentially leading to a payday for investors.

Newcomers· Oct 16

The newcomer is focusing on ContraFect Corporation's ($CFRX) resistance levels at 1.10, 1.18, 1.23, and 1.30, indicating a potential small price push.
The newcomer is interested in ContraFect Corporation ($CFRX) as a stock to watch, possibly due to its recent price movement and potential for further growth.
The newcomer is considering ContraFect Corporation ($CFRX) as a short squeeze/Low float runner play, potentially due to its low float and high short interest, making it a speculative investment opportunity.

Generated by AI

ContraFect

Social

Nov 9

Sentiment

Bullish· Jun 9

Bearish· Apr 17

Topics

Announcements· Oct 16

Technical Analysis· Jun 9

Community

Regulars· Oct 16

Newcomers· Oct 16

Also Discussed

ContraFect Corporation

Company Information

Location

Also Discussed

Social

Nov 9

Sentiment

Bullish· Jun 9

Bearish· Apr 17

Topics

Announcements· Oct 16

Technical Analysis· Jun 9

Community

Regulars· Oct 16

Newcomers· Oct 16